Search

Displaying results 921 - 930 of 10000 in total
  1. Drug

    Ioversol

    go.drugbank.com/drugs/DB09134
    ApprovedInvestigational

    Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. … [L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left

    Categories: Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media, X-Ray Contrast ActivitySynonyms: N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
  2. Drug

    Olive oil

    go.drugbank.com/drugs/DB09567
    ApprovedInvestigational

    Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].

    Mixtures: SmofKabiven Low Osmo peripher Emulsion zur Infusion, OLICLINOMEL N7-1000 EMULSION FOR INFUSION
  3. Drug

    Avacincaptad pegol

    go.drugbank.com/drugs/DB15165
    ApprovedInvestigational

    AMD eventually progresses to bilateral and irreversible loss of vision, whether or not the patients have the non-neovascular (dry) or the neovascular (wet) form of AMD. … [A260801] Avacincaptag pegol was approved by the FDA on August 4, 2023, under the brand name IZERVAY for the treatment of GA secondary to AMD.

  4. Drug

    D-glucose

    go.drugbank.com/drugs/DB01914
    ApprovedInvestigationalVet approved

    L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative.

    Mixtures: Dextrose and Electrolyte No. 75, Dextrose and Electrolyte No. 48
  5. Drug

    Cyclandelate

    go.drugbank.com/drugs/DB04838
    ApprovedWithdrawn

    It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.

  6. Target

    Non-heme chloroperoxidase

    go.drugbank.com/bio_entities/BE0001985
    EnzymePseudomonas fluorescens

    Polypeptides: Non-heme chloroperoxidase
  7. Target

    Non-fluorescent flavoprotein

    go.drugbank.com/bio_entities/BE0004235
    TargetPhotobacterium leiognathi

    Polypeptides: Non-fluorescent flavoprotein
  8. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).

  9. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  10. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

    Synonyms: (±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol, 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol